These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34550621)

  • 41. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.
    Gan-Or Z; Bar-Shira A; Mirelman A; Gurevich T; Kedmi M; Giladi N; Orr-Urtreger A
    Neurogenetics; 2010 Feb; 11(1):121-5. PubMed ID: 19458969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report.
    Tang Y; Wei L; Wu Z; Xu P; Mo M
    BMC Neurol; 2023 Jun; 23(1):226. PubMed ID: 37301871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
    Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
    Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
    Lee CY; Menozzi E; Chau KY; Schapira AHV
    J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
    Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Ayoub M; Mory A; Nassar M; Kurolap A; Peretz-Aharon J; Gershoni-Baruch R
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1067-71. PubMed ID: 26169695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
    Goldstein O; Gana-Weisz M; Cohen-Avinoam D; Shiner T; Thaler A; Cedarbaum JM; John S; Lalioti M; Gurevich T; Bar-Shira A; Mirelman A; Giladi N; Orr-Urtreger A
    Mol Genet Metab; 2019 Dec; 128(4):470-475. PubMed ID: 31662221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Filippi M; Balestrino R; Basaia S; Agosta F
    Mov Disord; 2022 Jul; 37(7):1375-1393. PubMed ID: 35521899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.
    Schindlbeck KA; Vo A; Nguyen N; Tang CC; Niethammer M; Dhawan V; Brandt V; Saunders-Pullman R; Bressman SB; Eidelberg D
    Cereb Cortex; 2020 May; 30(5):2867-2878. PubMed ID: 31813991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
    Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
    Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
    Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
    Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
    Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
    Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
    Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Exploratory Study Using Electronic Medical Records to Assess the Feasibility of Establishing Cohorts of Patients with Genetic Causes of Parkinson's Disease.
    Lee SJ; Shaw PM; Thornton B; Kumar A; Eizik M; Goldstaub D; Braun T; Teper G; Pai JK; Chodick G; Bienfait K; Levitan D; Beller D; Chris Min K; Jonathan D; Voss T; Fox CS; Aubrey Stoch S; Struyk AF; Vainstein G
    J Parkinsons Dis; 2022; 12(5):1645-1653. PubMed ID: 35466950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Avenali M; Cerri S; Ongari G; Ghezzi C; Pacchetti C; Tassorelli C; Valente EM; Blandini F
    Mov Disord; 2021 May; 36(5):1267-1272. PubMed ID: 33617695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    den Heijer JM; Kruithof AC; Moerland M; Walker M; Dudgeon L; Justman C; Solomini I; Splitalny L; Leymarie N; Khatri K; Cullen VC; Hilt DC; Groeneveld GJ; Lansbury P
    Mov Disord; 2023 Jul; 38(7):1197-1208. PubMed ID: 37195859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.